2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

508. Bone Marrow Failure: Acquired: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Plasma Cell Disorders, LGL, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4922 CXCL9 as a marker of potential efficacy of anti-IFN-γ therapy in idiopathic aplastic anemia

Serhan Unlu, MD, Charlotte Zurowski2, Karol K Gostomczyk3, Zachary Brady, BS4, Maxwell Hou, N/A5, Vibha Balasubramaniam6, Akram Abushamma, MD7, Ana Plesca, MD8, Jackson Hensley, N/A9, Aashray Mandala, BS10, Kartik Lakhotiya, MS11, Varun K. Venkatesh, N/A12, Ajitesh Reddy Busireddy, N/A13, Luca Guarnera, MD14, Arda Durmaz, PhD15, Atsushi Marumo, MD16, Carmelo Gurnari, MD,PhD17, Carlos Bravo-Perez, MD18, Valeria Visconte, PhD19, Jaroslaw P. Maciejewski, MD, PhD, FACP20
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
13 Cleveland Clinic, Cleveland, Ohio, United States
14 Cleveland Clinic, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
15 Cleveland Clinic, Cleveland, Ohio, United States
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Cleveland Clinic, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
18 Cleveland Clinic, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, Murcia, Spain
19 Cleveland Clinic, Cleveland, Ohio, United States
20 Cleveland Clinic, Cleveland, Ohio, United States

Introduction. Modulating cellular immune system with calcineurin inhibitors or depletion of lymphocytes in severe cases of immune-mediated bone marrow failure syndromes (BMFS) have been the main pillars of all non-transplant therapy strategies. Recently, anti-IFN-γ therapy has been shown to be efficacious in hemophagocytic lymphohistiocytosis (HLH), a fulminant inflammatory condition associated with BMF. For decades IFN-γ has been implicated in the pathogenesis of aplastic anemia (AA) and other BMFS via its direct cytotoxic effects, indirectly due to up modulation of FAS/FASL and HLA or indirectly through activation of immune cells. Previous therapies directed against TNF-α and IL-2 receptor yielded mixed results. So far, no treatment attenuating cytokine response in BMFS has entered routine practice. For IFN-γ, one difficulty was availability of suitable neutralizing antibodies and use serum levels of IFN-γ as a biomarker due to localized effects and short half-life. These shortcomings have been recently overcome through availability of Gamifant in HLH wherein measurement of serum levels of IFN-γ induced cytokines, including CXCL9 as a more stable biomarker, shown to be predictive of response in HLH.

Aim. To investigate possible applications of anti IFN-γ therapy in AA, we measured levels of CXCL9 and correlated them with treatment response and disease severity. 

Methods. In our single center preclinical study, we analyzed levels of CXCL9 in sera of 103 BMFS patients at different timepoints. A ThermoFisher ELISA kit with an analytic sensitivity of 20pg/mL and an assay range of 20-6000pg/mL was used.

Results. In total we analyzed the following cases: AA (n=47, 28 unique patients), T-LGLL (n=49, 34 unique) and hematologic disease controls including MPN (n=11, 6 unique) and MDS/AML (n=8, 8 unique). A cohort of 20 healthy controls (HC) were used for comparison. Median age of patients was 58 for AA (14 males/14 females). In HC, median CXCL9 level was 224pg/mL (range 48-1883pg/mL).   

Of 28 AA, 19 had serial sera collected; 7 had active disease at first sampling, with a median CXCL9 level of 424pg/mL (range 275-1314pg/mL) doubling the one of the HC and 8 had their disease in remission with a median CXCL9 level of 379pg/mL. Of the 7 patients who had an active disease at initial sampling, there was no sustained CR after an average follow up of 4.9 mo. (range 1-9 mo.). During follow up, median CXCL9 level was higher (1035pg/mL, range 423-2351pg/mL; P=0.078). In this group, 6 patients were pancytopenic. Most common treatment was CsA (n=2) and TPO-RAs (n=2). Out of 12 patients who were first tested in remission, 7 remained in remission and 5 had recurrence of disease. Median CXCL9 level in those who had relapse was 3066pg/mL (range 1375-3849pg/mL) while those who remained in remission had a median CXCL9 level of 317pg/mL (range 136-979pg/mL) (P=0.0025).  Interestingly, patients who were in remission and stayed in remission (n=7) had a lower baseline CXCL9 levels compared to those later relapsed (n=5) (244 pg/mL vs 1398pg/mL (P=0.0051). Mean follow up of patients who were first tested in remission was 7 mo. (range 2-10 mo.). All these patients (n=8) remained mildly anemic. CsA therapy was continued in 5 of them.  PNH clone was associated with lower CXCL9 levels, 44 patients with a PNH clone (median grans clone size: 41%, range 1.5%-99.9) at the time of testing having a median CXCL9 level of 423.9 pg/mL (range, 91 pg/mL- above detection) in comparison to 23 AA without a PNH clone at the time of testing (<1% grans clone) with a median CXCL9 level of 935pg/mL (range 173-3790pg/mL p=0.027).

Compared to HC, we also observed increased median CXCL9 levels in T-LGLL (n=49, 1798pg/mL, range 93pg/mL-above detection threshold) suggesting involvement of this cytokine in this clonal lymphoproliferative disorder.

Conclusion. Our preliminary analysis of CXCL9 shows a correlation of serum levels with active or relapsed disease status in AA. Higher baseline levels were observed in patients with AA in remission and later relapsed compared to those who remain in durable remission. Notwithstanding the possibility that CXCL9 predictive value is limited to HLH, our results suggest a possible role of CXCL9 levels as biomarker for anti-IFN therapy in AA and possibly in other overlapping syndromes like T-LGLL. Expanded screening and correlation with INF-y and other cytokines are warranted and ongoing in our laboratory.

 

We thank Sobi, Inc. for funding support

Serhan Unlu, MD: No relevant conflicts of interest to declare.